argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [2] - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] Upcoming Events - argenx will host a conference call and audio webcast on February 29, 2024, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update [1] - The live call can be accessed on the Investors section of the argenx website, with a replay available for approximately one year following the presentation [1] Product Development - The company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises [2]